Statins: The case for higher, individualized starting doses

Peter H. Jones, MD
Associate Professor of Medicine; Director of Clinical Trials; Co-director, Lipid Metabolism and Atherosclerosis Clinic; Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, TX

Address: Peter H. Jones, MD, FACP, 6565 Fannin Street, A601, Houston, TX 77030; e-mail jones@bcm.tmc.edu

The author has indicated that he has received research grants from the Pfizer, AstraZeneca, Kos, and Abbott corporations.

Peter H. Jones, MD
Associate Professor of Medicine; Director of Clinical Trials; Co-director, Lipid Metabolism and Atherosclerosis Clinic; Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, TX

Address: Peter H. Jones, MD, FACP, 6565 Fannin Street, A601, Houston, TX 77030; e-mail jones@bcm.tmc.edu

The author has indicated that he has received research grants from the Pfizer, AstraZeneca, Kos, and Abbott corporations.

Peter H. Jones, MD
Associate Professor of Medicine; Director of Clinical Trials; Co-director, Lipid Metabolism and Atherosclerosis Clinic; Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, TX

Address: Peter H. Jones, MD, FACP, 6565 Fannin Street, A601, Houston, TX 77030; e-mail jones@bcm.tmc.edu

The author has indicated that he has received research grants from the Pfizer, AstraZeneca, Kos, and Abbott corporations.